Am J Perinatol 2019; 36(14): 1504-1509
DOI: 10.1055/s-0039-1678555
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?

Sharandeep Kaur
1   Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
,
2   Section of Neonatology, Department of Pediatrics, Foothills Medical Centre, Cumming School of Medicine, University of Calgary, Alberta, Canada
3   Alberta Children's Hospital Research Institute, University of Calgary, Alberta, Canada
,
Amuchou Singh Soraisham
2   Section of Neonatology, Department of Pediatrics, Foothills Medical Centre, Cumming School of Medicine, University of Calgary, Alberta, Canada
3   Alberta Children's Hospital Research Institute, University of Calgary, Alberta, Canada
› Author Affiliations
Further Information

Publication History

18 June 2018

28 December 2018

Publication Date:
06 February 2019 (online)

Abstract

Objective Patent ductus arteriosus (PDA) is the most common cardiovascular problem of prematurity. Our objective was to examine the effect of postmenstrual age (PMA) on response to medical PDA treatment.

Study Design This retrospective cohort study included infants ≤ 32 weeks' gestational age (GA) who received nonsteroidal anti-inflammatory drugs (NSAIDs) for PDA treatment. Response was positive if echocardiogram showed closed or small PDA or no further treatment was required. Baseline characteristics between responders and nonresponders were compared. Multivariable logistic regression analysis with generalized estimating equations was used to analyze the association between PMA and response.

Results A total of 183 infants with a mean GA of 26.4 ± 2.2 weeks and birth weight of 870 ± 313 g received 257 courses of NSAIDs. Positive response rate to the first course was 65.6%. Two and three courses were given in 62 and 12 infants, with response rates of 48.4 and 50%, respectively. Surgical ligation of PDA occurred in 30 (16.4%) infants. Multivariable logistic regression analysis with generalized estimating equations revealed that PMA was not associated with a positive response (adjusted odds ratio [aOR]: 0.88; 95% confidence interval [CI]: 0.71–1.10). GA at birth remained the most influential factor (aOR: 1.33; 95% CI: 1.02–1.73).

Conclusion GA rather than PMA is the strongest predictor for a positive response in medical PDA treatment.

 
  • References

  • 1 Sellmer A, Bjerre JV, Schmidt MR. , et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed 2013; 98 (06) F505-F510
  • 2 Thébaud B, Lacaze-Mazmonteil T. Patent ductus arteriosus in premature infants: a never-closing act. Paediatr Child Health 2010; 15 (05) 267-270
  • 3 Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat?. J Perinatol 2010; 30 (Suppl): S31-S37
  • 4 Mitra S, Florez ID, Tamayo ME. , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA 2018; 319 (12) 1221-1238
  • 5 Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007; 151 (06) 629-634
  • 6 Brash AR, Hickey DE, Graham TP, Stahlman MT, Oates JA, Cotton RB. Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 1981; 305 (02) 67-72
  • 7 Brundin T, Norberg KA, Söderlund S. Lack of adrenergic nerves in the circular smooth muscles of ductus arteriosus persistens. Scand J Thorac Cardiovasc Surg 1971; 5 (01) 16-18
  • 8 McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics 1978; 62 (05) 706-712
  • 9 Popat H, Kapoor V, Travadi J. Patent ductus arteriosus in infants <29 weeks gestation--outcomes and factors affecting closure. Indian Pediatr 2012; 49 (08) 615-620
  • 10 Louis D, Wong C, Ye XY, McNamara PJ, Jain A. Factors associated with non-response to second course indomethacin for PDA treatment in preterm neonates. J Matern Fetal Neonatal Med 2018; 31 (11) 1407-1411
  • 11 Halliday HL, Hirata T, Brady JP. Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications. Pediatrics 1979; 64 (02) 154-159
  • 12 Benitz WE. ; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics 2016;137(1)
  • 13 Kresch MJ, Moya FR, Ascuitto RJ, Ross-Ascuitto NT, Heusser F. Late closure of the ductus arteriosus using indomethacin in the preterm infant. Clin Pediatr (Phila) 1988; 27 (03) 140-143
  • 14 Boo NY, Mohd-Amin I, Bilkis AA, Yong-Junina F. Predictors of failed closure of patent ductus arteriosus with indomethacin. Singapore Med J 2006; 47 (09) 763-768
  • 15 Tschuppert S, Doell C, Arlettaz-Mieth R. , et al. The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates: size matters. J Thorac Cardiovasc Surg 2008; 135 (01) 78-82
  • 16 Erdeve O, Yurttutan S, Altug N. , et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2012; 97 (04) F279-F283
  • 17 Sivanandan S, Bali V, Soraisham AS, Harabor A, Kamaluddeen M. Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. Am J Perinatol 2013; 30 (09) 745-750